Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics has issued 212,250,000 unlisted options as part of an employee incentive scheme, with each option carrying an exercise price of US$0.006 and expiring on April 15, 2031. The move expands the company’s pool of unquoted equity-based awards, aligning staff incentives with long-term shareholder value and potentially increasing future equity dilution if the options are exercised.
The new options, which are not intended to be quoted on the ASX, form part of Alterity’s ongoing approach to remunerate and retain employees using performance-linked securities. This structure underscores management’s focus on incentivising key personnel over the medium to long term while signalling to investors a possible future increase in the number of ordinary shares on issue.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the ticker ATH. The company operates in the life sciences sector, focusing on the development of therapeutic products, though this filing centers on its capital and incentive structures rather than specific drug programs or markets.
Average Trading Volume: 5,614,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more insights into ATH stock on TipRanks’ Stock Analysis page.